Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group.

PURPOSE: The aim of this phase II study was to evaluate the activity and safety of the combination of cisplatin and vinorelbine with thoracic radiotherapy in unresectable locally advanced stage III non-small cell lung cancer (NSCLC). The primary endpoint was the objective response rate (ORR). Secondary objectives included toxicity profile, progression-free survival (PFS), and overall survival (OS). MATERIALS AND METHODS: A total of 48 NSCLC patients were enrolled (median age 60 years, 52% stage IIIA and 48% stage IIIB, 52% adenocarcinoma). Patients received three cycles of chemotherapy every 21 days [intravenous cisplatin 80 mg/m2 and intravenous vinorelbine 25 mg/m2 on day 1 and oral vinorelbine on day 8 (60 mg/m2)] concurrent with radiotherapy (66 Gy, administered at 1.8 Gy per day, five consecutive days per week). RESULTS: ORR was 79.2% (72.9% showing partial response and 6.3% showing complete response). With a median follow-up of 20.7 months, median PFS was 12 months and median OS was 36 months. Grade 3/4 toxicities were: neutropenia (14.5%), anaemia (6.2%), vomiting (2%), and oesophagitis (4.2%). No toxic deaths were reported. CONCLUSION: This combined regimen shows efficacy and a manageable safety profile. PFS and OS outcomes are encouraging and warrant further research.

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.

PURPOSE: This single arm, phase II study aims to evaluate the role of epidermal growth factor receptor-tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent chemoradiotherapy (cCRT) in unresectable locally advanced non-small-cell lung cancer (NSCLC). METHODS: Patients with unresectable stage IIIA o dry IIIB NSCLC with no evidence of tumor progression after receiving a standard cCRT regimen with curative intent were included. Oral erlotinib 150 mg/day was administered within 4-6 weeks after the end of the cCRT for a maximum of 6 months if no disease progression or intolerable toxicity occurred. Primary end point was the progression-free rate (PFR) at 6 months. Secondary end points included time to progression (TTP) and overall survival (OS). RESULTS: Sixty-six patients were enrolled and received maintenance treatment with erlotinib [average: 4.5 months (95 % CI 4.0-5.0)]. PFR at 6 months was 63.5 % (41/66). With a median follow-up of 22.7 months (95 % CI 13.5-37.1), the median TTP was 9.9 months (95 % CI 6.2-12.1), and the median OS was 24.0 months (95 % CI 17.3-48.6). Most common adverse events (AEs) related to erlotinib were rash (78.8 %; 16.7 % grade 3), diarrhea (28.8 %; 1.5 % grade 3), fatigue (15.2 %; 1.5 % grade 3), anorexia (7.6 %; 1.5 % grade 3) and vomiting (4.6 %; none grade 3). Five patients (7.6 %) were withdrawn due to AEs. CONCLUSIONS: Erlotinib as maintenance therapy is an active treatment after cCRT in unselected patients with stage III NSCLC, reaching a 6-month PFR of 63.5 % and a median OS of 24 months. The safety profile of maintenance erlotinib was as expected and manageable.

[Prostate adenocarcinoma and synchcronous multiple myeloma: a case report]. / Adenocarcinoma prostático y mieloma múltiple sincrónicos: a propósito de un caso.

PURPOSE: To report a case of synchronous prostatic cancer with multiple myeloma as inusual neoplasm presentation. To indicate the clinical data that they help to suspect the myeloma presence in the prostate bone metastatic disease. CASE REPORT: Patient 63 years old diagnosed of prostatic carcinoma with bone metastasis and BAC good responsive, who have clinical deterioration, hypercalcemia and renal insufficiency. RESULTS: The presacred mass biopsy and extension study to find one second tumour (myeloma). CONCLUSION: The presence of multiple myeloma must be to rule out when there are bone lytics injuries, well biochemical evolution with therapy and clinical deterioration, hypercalcemia and quickly progressive renal insufficiency.

Carcinoma adenoide quístico de mama: a propósito de un caso / Adenoid cystic carcinoma of the breast. Apropos of a case

Objetivo: Describir un tipo de carcinoma mamario inusual y poco frecuente, con características definitorias propias. Caso clínico: Se presenta el caso de una mujer diagnosticada de este tipo de neoplasia y se realiza un comentario sobre los datos publicados hasta el momento. Resultados: Se analiza el comportamiento de este tumor en relación con otros tumores mamarios, su manejo clínico y tratamiento. Conclusiones: El carcinoma adenoide quístico es una entidad clinicopatológica diferente del carcinoma ductal o lobulillar infiltrante. Su tratamiento no se realiza según los parámetros determinantes en otros cánceres mamarios. Su evolución y comportamiento biológico parecen más favorables

Objective: To describe an unusual and infrequent type of breast carcinoma with specific defining characteristics. Case report: We present the case of a woman with cystic adenoid carcinoma and review the literature published on this entity to date. Results: The behavior of this tumor in relation to other breast tumors, and its clinical management and treatment are analyzed. Conclusions: Cystic adenoma of the breast is a distinct clinicopathological entity from infiltrating ductal or lobular breast carcinoma. Its treatment is not based on parameters that are determinant in other breast cancers. Its outcome and biological behavior seem more favorable

[Wilms tumor in the adult]. / Tumor de Wilms del adulto.

OBJECTIVE: To report a case of Wilms' tumor in an adult patient. METHODS: The records of an adult patient with renal tumor is reviewed. RESULTS: A 23-year-old male consulted for hematuria. Physical examination and patient assessment by ultrasound and CT showed a solid tumor in the right kidney. The patient was submitted to radical surgery. Pathological analysis demonstrated a biphasic nephroblastoma (Wilms' tumor) with infiltration of renal hilar fat (stage II). After surgery, adjuvant chemotherapy with vincristine-actinomycin D was administered for 60 weeks. CONCLUSIONS: Although rare in adults, Wilms' tumor should be included in the differential diagnosis of all renal tumors. Treatment is usually by surgery and chemotherapy with or without radiotherapy, depending on tumor stage.